Krystal Biotech (KRYS) Announces Proposed $200M Stock Offering

Krystal Biotech (KRYS) Prices 2.67M Share Offering at $75/sh

Krystal Biotech, Inc. (NASDAQ: KRYS) the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share. The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Companys common stock offered in the public offering. The gross proceeds to the Company from this offering are expected to be approximately $200 million, before deducting the underwriting discounts and commissions and other... More

Krystal Biotech (KRYS) PT Raised to $140 at Chardan Capital Markets, Following Clinical Business Update

Chardan Capital Markets analyst Geulah Livshits raised the price target on Krystal Biotech (NASDAQ: KRYS) to $140.00 (from $123.00) while maintaining a Buy rating.

Krystal Biotech (KRYS) PT Raised to $125 at Goldman Sachs

Goldman Sachs analyst Madhu Kumar raised the price target on Krystal Biotech (NASDAQ: KRYS) to $125.00 (from $85.00) while maintaining a Buy rating.

"Overall, we view this as a positive outcome for the HSV GT platform and thus maintain our KRYS Buy rating and increase... More

Krystal Biotech (KRYS) PT Raised to $124 at H.C. Wainwright, Following Clinical Business Update

H.C. Wainwright analyst Joseph Pantginis raised the price target on Krystal Biotech (NASDAQ: KRYS) to $124.00 (from $103.00) while maintaining a Buy rating.

Krystal Biotech (KRYS) PT Raised to $111 at Cowen

Cowen analyst Ritu Baral raised the price target on Krystal Biotech (NASDAQ: KRYS) to $111.00 (from $89.00) while maintaining an Outperform rating.

The analyst commented, "KRYS announced positive topline data from the Ph3 GEM-3 trial of Vyjuvek (fka B-VEC) in DEB. The study met its... More

Krystal Biotech (KRYS) call put ratio 1 call to 2.9 puts as shares rally 119% after data release

Krystal Biotech (NASDAQ: KRYS) 30-day option implied volatility is at 131; compared to its 52-week range of 45 to 325 after topline data expected from the pivotal GEM-3 trial evaluating B-VEC. Call put ratio 1 call to 2.9 puts as shares rally 119%.

Increasing unusual call option volume: CBRE HTA MPLN CNDT NUAN KRYS

Increasing unusual call option volume: CBRE HTA MPLN CNDT NUAN KRYS

Increasing unusual option volume: HTA KRYS CARS EWG NRXP

Increasing unusual option volume: HTA KRYS CARS EWG NRXP

Pre-Open Stock Movers 11/29: (KRYS) (ADGI) (TWTR) Higher; (MRK) (UPS) Lower (more...)

Pre-Open Stock Movers:

Krystal Biotech, Inc., (NASDAQ: KRYS) 142.6% HIGHER; announced positive topline results from the pivotal GEM-3 trial of investigational beremagene geperpavec (B-VEC), now known as VYJUVEKTM, for the treatment of dystrophic Epidermolysis Bullosa (dystrophic EB). The primary endpoint of the trial evaluated complete wound healing of topical VYJUVEKTM compared to placebo at six-month timepoints and met statistical significance. VYJUVEKTM is the first non-invasive, topical and redosable gene therapy in development, and the only genetically corrective... More

Krystal Biotech (KRYS) Surges 125% Following Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech (NASDAQ: KRYS) Surges 125% Following Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech (KRYS) Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc., (Krystal) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases,... More